Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease

Erickson KF, Chertow GM, Goldhaber-Fiebert JD

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.7326/0003-4819-159-6-201309170-00004

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Age of Onset; Aged; Aged, 80 and over; Benzazepines /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Disease Progression; Female; Glomerular Filtration Rate /drug effects; Humans; Kidney Failure, Chronic /etiology; Life Expectancy; Male; Markov Chains; Middle Aged; Polycystic Kidney, Autosomal Dominant /complications /drug therapy /physiopathology; Quality-Adjusted Life Years

AccessionNumber
22013043052

Date bibliographic record published
18/10/2013